Chemotherapy Drug FUdR may Resolve Discrepancies on Aging

by Bidita Debnath on  February 24, 2016 at 2:14 AM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

We mammals are not so different from tiny C. elegans worms, in matters of the fundamental molecular biology of aging. Some of the biggest differences only serve to make them convenient research models.
 Chemotherapy Drug FUdR may Resolve Discrepancies on Aging
Chemotherapy Drug FUdR may Resolve Discrepancies on Aging

But one distinction - their ability to asexually reproduce exact copies of themselves - may have led to many research discrepancies. The reason, according to a new Brown University-led study, is that the drug scientists use prevent such confusing reproduction turns out to help aging worms rebound from stress, thereby significantly lengthening their lifespan in some cases.

In the study in Mechanics of Ageing and Development, neuroscience Professor Anne Hart, lead author Edward Anderson and colleagues identify the human chemotherapy drug FUdR as the culprit. Their detailed experiments show that the drug goes well beyond squelching worm reproduction. It also triggers stress response and turns on DNA repair pathways (that are also found in mammals) that allow the worms to better endure adverse conditions such as saltiness, heat, or low oxygen.

"We can explain a lot of the disagreement in the C. elegans aging field by realizing that FuDR can dramatically change the answer," Hart said. Reviewing dozens of studies with discordant findings across many genetic models of worm longevity, Anderson found that a consistent difference-maker was using FUdR.

"There were very different effects in published papers that had different doses of FUdR in them," said Anderson, formerly a technician in Hart's lab and now a biology graduate student at Brown. "Sometimes it's a very profound disagreement." Moreover, some other studies may involve FUdR-related discrepancies but insufficient documentation of the methods prevented Anderson from being sure.

An instructive mistake

One of the first studies Anderson examined was a mysterious one from within the Hart lab that had employed FUdR in the conventional way for an aging study, leading to results they couldn't reconcile with published results. "We didn't expect to have this happen," Hart said. "We decided to figure out what was going on."

They started to suspect FuDR might be the difference. Studies were beginning to enter the scientific literature - and rumors were welling up at conferences - suggesting it might affect more than just reproduction in worms.

To truly prove it or rule it out, they began a series of experiments testing FUdR's effects in the worms and found that rather than simplifying their experiments on worm longevity, the drug was indeed dramatically changing their results.

In the absence of any stress, FUdR makes no difference to lifespan in normal worms, they confirmed. But when worms were exposed to a modest concentration of salt, animals who were not exposed to FUdR had only half the lifespan of those who were exposed to the drug. Meanwhile, adding even more FUdR caused even longer lifespan under salt stress. A tenfold increase in FUdR concentration extended lifespan by a factor of three. Other experiments suggested that FUdR causes better stress resistance in hot or low-oxygen conditions.

Further research revealed details of how FUdR protects the worms from stress. They found evidence that the drug turns on the gene that produces the protein "FOXO," a master regulator of stress resistance in many organisms that is often central in longevity studies. They also found that exposure to FUdR forced DNA mutations that then activated a DNA-repair process. That process, once activated, also fixes a lot of DNA damage caused by environmental stresses, including dreaded "double-strand breaks," a clean severing of the DNA molecule.

Time to retire FUdR?

While many scientists in the biology of aging field may now find it helpful to reconcile disparate results of the past, Hart said, the new findings should also give them pause about continuing to use FUdR in the future.

It's now clear that the drug has high potential to confound aging studies, the authors wrote. If it's to be used at all, then it's important for scientists in their published research to be very clear about if it was used and to state the genetic lines of worms and experimental conditions of the research. But, it may be best not to use it at all, they wrote.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

Drug Toxicity Chronic Lymphocytic Leukemia Hodgkins Lymphoma Non-Hodgkins Lymphoma Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Ageing and Sleep Peritoneal Cancer Rhabdomyosarcoma 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive